Migraine        

FOI REFERENCE: 24404 FOI DATE: 4^th October 2024          

A. Please provide the number of migraine patients treated in the last 4 months with:

• Atogepant (Aquipta)                          18
• Erenumab (Aimovig)                          0
• Eptinezumab (Vyepti)                         0
• Fremanezumab (Ajovy)                      0         
• Galcanezumab (Emgality)                  0
• Rimegepant (Vydura)                         9
• Botulinum Toxin (i.e., Botox, Dysport, Xeomin) Unable to determine

B. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:  We are unable to provide a response as by clinical indication is not held within EMIS our electronic pharmacy system.

C. How many patients have you treated in the last 4 months for acute migraine with:

• Rimegepant (Vydura)                                  0

D. Are you required to complete Blueteq for the following product classes:

Botulinum Toxin (Botox, Dysport, Xeomin) No                                  

Monoclonal antibodies (e.g. fremanezumab, erenumab, galcanezumab, eptinezumab) Yes     

Gepants (e.g. rimegepant, atogepant) No